You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer
Contributor:
Luker, Gary D;
Yang, Jinming;
Richmond, Ann;
Scala, Stefania;
Festuccia, Claudio;
Schottelius, Margret;
Wester, Hans-Jürgen;
Zimmermann, Johann
Published:
Oxford University Press (OUP), 2021
Published in:
Journal of Leukocyte Biology, 109 (2021) 5, Seite 969-989
Language:
English
DOI:
10.1002/jlb.2bt1018-715rr
ISSN:
0741-5400;
1938-3673
Origination:
Footnote:
Description:
<jats:title>Abstract</jats:title>
<jats:p>Signaling through chemokine receptor, C-X-C chemokine receptor type 4 (CXCR4) regulates essential processes in normal physiology, including embryogenesis, tissue repair, angiogenesis, and trafficking of immune cells. Tumors co-opt many of these fundamental processes to directly stimulate proliferation, invasion, and metastasis of cancer cells. CXCR4 signaling contributes to critical functions of stromal cells in cancer, including angiogenesis and multiple cell types in the tumor immune environment. Studies in animal models of several different types of cancers consistently demonstrate essential functions of CXCR4 in tumor initiation, local invasion, and metastasis to lymph nodes and distant organs. Data from animal models support clinical observations showing that integrated effects of CXCR4 on cancer and stromal cells correlate with metastasis and overall poor prognosis in &gt;20 different human malignancies. Small molecules, Abs, and peptidic agents have shown anticancer efficacy in animal models, sparking ongoing efforts at clinical translation for cancer therapy. Investigators also are developing companion CXCR4-targeted imaging agents with potential to stratify patients for CXCR4-targeted therapy and monitor treatment efficacy. Here, pre-clinical studies demonstrating functions of CXCR4 in cancer are reviewed.</jats:p>